person · Reporting owner

Harris Taylor C.

Disclosed activity across 6 companies

Tapewire entity: 33991
SEC CIK: 0001560168

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CUTERA INCCUTR · Entity 82936	Director · Chief Executive Officer	February 07, 2025	February 21, 2025
ESTABLISHMENT LABS HOLDINGS INC.ESTA · Entity 4473	Director	June 24, 2026	July 01, 2026
Hyperfine, Inc.HCAQ · Entity 6865	Director	January 26, 2021	January 27, 2021
PROCEPT BioRobotics CorpPRCT · Entity 4831	Director	June 09, 2026	June 10, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CUTERA INC

Report date February 07, 2025 · Filed February 21, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
COMMON STOCKSEC Table I · non-derivative	Direct	255,744	Reported balance After 2025-02-07 transaction · row 1 1 source row Row 1 · 2025-02-07 · Tax withholding · Disposed 4,620 · Balance 255,744 F1: Represents the total number of shares withheld by the Company to settle the Reporting Person's tax liability for 15,583 Restricted Stock Units vesting on February 7, 2025. Such withholding is required by the Company's 2019 Equity Incentive Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the total number of shares withheld by the Company to settle the Reporting Person's tax liability for 15,583 Restricted Stock Units vesting on February 7, 2025. Such withholding is required by the Company's 2019 Equity Incentive Plan.

ESTABLISHMENT LABS HOLDINGS INC.

Report date June 24, 2026 · Filed July 01, 2026 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	1,949	Reported balance After 2026-06-24 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2026-06-24 · Grant · Acquired 1,949 · Balance 1,949 F1: Represents an award of stock units under the Issuer's 2018 Equity Incentive Plan. The shares subject to the award vest as to 1/3 of the shares subject to the initial award on the yearly anniversary of the date of grant, subject to the Reporting Person continuing as a service provider through such date.
Common SharesSEC Table I · non-derivative	Direct	3,230	Reported balance After 2026-06-24 transaction · row 2 Amendment: may correct only part of an earlier disclosure. 1 source row Row 2 · 2026-06-24 · Grant · Acquired 1,773 · Balance 3,230 F2: Represents an award of stock units under the Issuer's 2018 Equity Incentive Plan. The shares subject to the award vest in full on the earlier of June 24, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through such date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents an award of stock units under the Issuer's 2018 Equity Incentive Plan. The shares subject to the award vest as to 1/3 of the shares subject to the initial award on the yearly anniversary of the date of grant, subject to the Reporting Person continuing as a service provider through such date.

F2: Represents an award of stock units under the Issuer's 2018 Equity Incentive Plan. The shares subject to the award vest in full on the earlier of June 24, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through such date.

Hyperfine, Inc.

Report date January 26, 2021 · Filed January 27, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B ordinary sharesSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2021-01-26 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-252002) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: As described in the issuer's registration statement on Form S-1 (File No. 333-252002) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.

PROCEPT BioRobotics Corp

Report date June 09, 2026 · Filed June 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	102,491	Reported balance After 2026-06-09 transaction · row 1 1 source row Row 1 · 2026-06-09 · Grant · Acquired 3,315 · Balance 102,491 F1: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.78 · Expires 2036-06-08	Direct	5,853	Reported balance After 2026-06-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-09 · Grant · Acquired 5,853 · Balance 5,853 F2: The Stock option was granted on June 9, 2026, and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.

F2: The Stock option was granted on June 9, 2026, and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

MyoKardia, Inc.

Report date November 17, 2020 · Filed November 19, 2020

Section 16 reporting ended · disclosed 2020-11-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-11-17 transaction · row 1 1 source row Row 1 · 2020-11-17 · Other · Disposed 42,559 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.50	Direct	Reported balance After 2020-11-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-11-17 · Disposition to issuer · Disposed 100,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.11	Direct	Reported balance After 2020-11-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-11-17 · Disposition to issuer · Disposed 49,400 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.40	Direct	Reported balance After 2020-11-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-11-17 · Disposition to issuer · Disposed 46,060 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price.

F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

Zeltiq Aesthetics Inc

Report date April 28, 2017 · Filed April 28, 2017

Section 16 reporting ended · disclosed 2017-04-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2017-04-28 transaction · row 1 1 source row Row 1 · 2017-04-28 · Disposition to issuer · Disposed 62,705 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc. a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer (the "Board"), whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all 62,705 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.81 · Expires 2026-02-01	Direct	Reported balance After 2017-04-28 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-04-28 · Disposition to issuer · Disposed 106,411 · Balance 0 F2: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares underlying this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.89 · Expires 2027-01-17	Direct	Reported balance After 2017-04-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-04-28 · Disposition to issuer · Disposed 22,232 · Balance 0 F2: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares underlying this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc. a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer (the "Board"), whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all 62,705 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes.

F2: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares underlying this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 24, 2026 Filed Jun 29, 2026 21:34 UTC	ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473	GrantCommon Shares	1,281	$0.00	$0.00	Disclosure SEC source: 0001628280-26-046089 · wk-form4_1782768866.xml · nonDerivative · entry 2 Harris Taylor C. · CIK 0001560168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,230 F2 · kind: Represents an award of stock units under the Issuer's 2018 Equity Incentive Plan. The shares subject to the award vest in full on the earlier of June 24, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through such date. Read SEC document
June 24, 2026 Filed Jun 29, 2026 21:34 UTC	ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473	GrantCommon Shares	1,949	$0.00	$0.00	Disclosure SEC source: 0001628280-26-046089 · wk-form4_1782768866.xml · nonDerivative · entry 1 Harris Taylor C. · CIK 0001560168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,949 F1 · kind: Represents an award of stock units under the Issuer's 2018 Equity Incentive Plan. The shares subject to the award vest as to 1/3 of the shares subject to the initial award on the yearly anniversary of the date of grant, subject to the Reporting Person continuing as a service provider through such date. Read SEC document
June 24, 2026 Filed Jul 1, 2026 22:10 UTC Amendment	ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473	GrantCommon Shares	1,773	$0.00	$0.00	Disclosure SEC source: 0001560168-26-000001 · wk-form4a_1782943800.xml · nonDerivative · entry 2 Harris Taylor C. · CIK 0001560168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,230 F2 · kind: Represents an award of stock units under the Issuer's 2018 Equity Incentive Plan. The shares subject to the award vest in full on the earlier of June 24, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through such date. Read SEC document
June 24, 2026 Filed Jul 1, 2026 22:10 UTC Amendment	ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473	GrantCommon Shares	1,949	$0.00	$0.00	Disclosure SEC source: 0001560168-26-000001 · wk-form4a_1782943800.xml · nonDerivative · entry 1 Harris Taylor C. · CIK 0001560168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,949 F1 · kind: Represents an award of stock units under the Issuer's 2018 Equity Incentive Plan. The shares subject to the award vest as to 1/3 of the shares subject to the initial award on the yearly anniversary of the date of grant, subject to the Reporting Person continuing as a service provider through such date. Read SEC document
June 09, 2026 Filed Jun 10, 2026 20:41 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	GrantStock Option (Right to Buy) · Derivative	5,853	$0.00 Strike: $28.78	$0.00	Disclosure SEC source: 0001628280-26-042267 · wk-form4_1781124114.xml · derivative · entry 2 Harris Taylor C. · CIK 0001560168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,853 Underlying: Common Stock · 5,853 shares Expires 2036-06-08 F2 · derivative.exercise_date: The Stock option was granted on June 9, 2026, and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document
June 09, 2026 Filed Jun 10, 2026 20:41 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	GrantCommon Stock	3,315	$0.00	$0.00	Disclosure SEC source: 0001628280-26-042267 · wk-form4_1781124114.xml · nonDerivative · entry 1 Harris Taylor C. · CIK 0001560168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,491 F1 · kind: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document
June 10, 2025 Filed Jun 12, 2025 20:25 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	GrantStock Option (Right to Buy) · Derivative	2,771	$0.00 Strike: $64.23	$0.00	Disclosure SEC source: 0001628280-25-030982 · wk-form4_1749759897.xml · derivative · entry 3 Harris Taylor C. · CIK 0001560168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,771 Underlying: Common Stock · 2,771 shares Expires 2035-06-09 F3 · derivative.exercise_date: The Stock option was granted on June 10, 2025 and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document
June 10, 2025 Filed Jun 12, 2025 20:25 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	GrantCommon Stock	1,538	$0.00	$0.00	Disclosure SEC source: 0001628280-25-030982 · wk-form4_1749759897.xml · nonDerivative · entry 1 Harris Taylor C. · CIK 0001560168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,176 F1 · kind: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. F2 · balance_after: Reported share balance adjusted to reflect the ownerhsip of 35,074 shares held in the name of The Harris Trust, of which Taylor Harris the the trustee. Read SEC document
February 07, 2025 Filed Feb 21, 2025 13:42 UTC	CUTERA INC CUTR · Entity 82936	Tax withholdingCOMMON STOCK	4,620	$0.44	$2,026.79	Disclosure SEC source: 0001628280-25-007065 · wk-form4_1740163359.xml · nonDerivative · entry 1 Harris Taylor C. · CIK 0001560168 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 255,744 F1 · shares: Represents the total number of shares withheld by the Company to settle the Reporting Person's tax liability for 15,583 Restricted Stock Units vesting on February 7, 2025. Such withholding is required by the Company's 2019 Equity Incentive Plan. Read SEC document
November 07, 2024 Filed Nov 13, 2024 17:07 UTC	CUTERA INC CUTR · Entity 82936	Tax withholdingCOMMON STOCK	3,794	$0.51	$1,916.35	Disclosure SEC source: 0001628280-24-047664 · wk-form4_1731535645.xml · nonDerivative · entry 1 Harris Taylor C. · CIK 0001560168 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,364 F1 · shares: Represents the total number of shares withheld by the Company to settle the Reporting Person's tax liability for 15,584 Restricted Stock Units vesting on November 7, 2024. Such withholding is required by the Company's 2019 Equity Incentive Plan. Read SEC document
October 24, 2024 Filed Nov 5, 2024 16:09 UTC	CUTERA INC CUTR · Entity 82936	GrantStock Option (Right to Buy) · Derivative	100,000	$0.00 Strike: $0.65	$0.00	Disclosure SEC source: 0001628280-24-045283 · wk-form4_1730840952.xml · derivative · entry 1 Harris Taylor C. · CIK 0001560168 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,060,622 Underlying: COMMON STOCK · 100,000 shares Expires 2031-10-23 F1 · derivative.exercise_date: The stock options vest 1/48 per month from October 24, 2024, subject to the Reporting Person continuing to be a service provider of the Company. F2 · derivative.expiration_date: The expiration date is subject to earlier expiration upon the termination of the Reporting Person's service with the Company. Read SEC document
August 07, 2024 Filed Aug 9, 2024 16:05 UTC	CUTERA INC CUTR · Entity 82936	Tax withholdingCOMMON STOCK	15,178	$1.03	$15,633.34	Disclosure SEC source: 0001628280-24-036467 · wk-form4_1723233913.xml · nonDerivative · entry 1 Harris Taylor C. · CIK 0001560168 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264,158 F1 · shares: Represents the total number of shares withheld by the Company to settle the Reporting Person's tax liability for 62,334 Restricted Stock Units vesting on August 7, 2024. Such withholding is required by the Company's 2019 Equity Incentive Plan. Read SEC document
July 15, 2024 Filed Jul 17, 2024 21:31 UTC	CUTERA INC CUTR · Entity 82936	GrantStock Option (Right to Buy) · Derivative	200,000	$0.00 Strike: $1.54	$0.00	Disclosure SEC source: 0001628280-24-032153 · wk-form4_1721266300.xml · derivative · entry 6 Harris Taylor C. · CIK 0001560168 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: COMMON STOCK · 200,000 shares Expires 2031-05-13 F2 · derivative.exercise_price: On July 15, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $1.54 per share. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: The shares subject to the option shall vest 1/48 per month from April 25, 2024, subject to the Reporting Person continuing to be a service provider through each such date. Read SEC document
July 15, 2024 Filed Jul 17, 2024 21:31 UTC	CUTERA INC CUTR · Entity 82936	Disposition to issuerStock Option (Right to Buy) · Derivative	200,000	$0.00 Strike: $2.23	$0.00	Disclosure SEC source: 0001628280-24-032153 · wk-form4_1721266300.xml · derivative · entry 5 Harris Taylor C. · CIK 0001560168 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: COMMON STOCK · 200,000 shares Expires 2031-05-13 F4 · derivative.exercise_date: The shares subject to the option shall vest 1/48 per month from April 25, 2024, subject to the Reporting Person continuing to be a service provider through each such date. Read SEC document
July 15, 2024 Filed Jul 17, 2024 21:31 UTC	CUTERA INC CUTR · Entity 82936	GrantStock Option (Right to Buy) · Derivative	735,295	$0.00 Strike: $1.54	$0.00	Disclosure SEC source: 0001628280-24-032153 · wk-form4_1721266300.xml · derivative · entry 4 Harris Taylor C. · CIK 0001560168 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 735,295 Underlying: COMMON STOCK · 735,295 shares Expires 2030-08-18 F2 · derivative.exercise_price: On July 15, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $1.54 per share. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: One-fourth of the shares subject to the option will be eligible to vest upon the date the 30 calendar-day trailing average closing price of the Issuer's common stock first meets each of the following levels within four years of the grant date: $20.00, $25.00, $30.00, and $35.00. Once a level is attained, one-fourth of the options subject to such tranche will vest on the later of (i) the date such level is attained or (ii) August 7, 2024. The remaining options in such tranche will vest over the next 12 quarters, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
July 15, 2024 Filed Jul 17, 2024 21:31 UTC	CUTERA INC CUTR · Entity 82936	Disposition to issuerStock Option (Right to Buy) · Derivative	735,295	$0.00 Strike: $11.02	$0.00	Disclosure SEC source: 0001628280-24-032153 · wk-form4_1721266300.xml · derivative · entry 3 Harris Taylor C. · CIK 0001560168 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: COMMON STOCK · 735,295 shares Expires 2030-08-18 F3 · derivative.exercise_date: One-fourth of the shares subject to the option will be eligible to vest upon the date the 30 calendar-day trailing average closing price of the Issuer's common stock first meets each of the following levels within four years of the grant date: $20.00, $25.00, $30.00, and $35.00. Once a level is attained, one-fourth of the options subject to such tranche will vest on the later of (i) the date such level is attained or (ii) August 7, 2024. The remaining options in such tranche will vest over the next 12 quarters, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
July 15, 2024 Filed Jul 17, 2024 21:31 UTC	CUTERA INC CUTR · Entity 82936	GrantStock Option (Right to Buy) · Derivative	25,327	$0.00 Strike: $1.54	$0.00	Disclosure SEC source: 0001628280-24-032153 · wk-form4_1721266300.xml · derivative · entry 2 Harris Taylor C. · CIK 0001560168 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,327 Underlying: COMMON STOCK · 25,327 shares Expires 2030-05-19 F2 · derivative.exercise_price: On July 15, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $1.54 per share. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · derivative.exercise_date: One-third of the shares subject to the option vested on May 19, 2024 and one-third of the shares subject to the option vest each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
July 15, 2024 Filed Jul 17, 2024 21:31 UTC	CUTERA INC CUTR · Entity 82936	Disposition to issuerStock Option (Right to Buy) · Derivative	25,327	$0.00 Strike: $16.84	$0.00	Disclosure SEC source: 0001628280-24-032153 · wk-form4_1721266300.xml · derivative · entry 1 Harris Taylor C. · CIK 0001560168 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: COMMON STOCK · 25,327 shares Expires 2030-05-19 F1 · derivative.exercise_date: One-third of the shares subject to the option vested on May 19, 2024 and one-third of the shares subject to the option vest each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
June 04, 2024 Filed Jun 6, 2024 20:32 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	GrantStock Option (Right to Buy) · Derivative	2,526	$0.00 Strike: $67.29	$0.00	Disclosure SEC source: 0001628280-24-027061 · wk-form4_1717705944.xml · derivative · entry 4 Harris Taylor C. · CIK 0001560168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,526 Underlying: Common Stock · 2,526 shares Expires 2034-06-03 F3 · derivative.exercise_date: The Stock Option was granted on June 4, 2024 and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document
June 04, 2024 Filed Jun 6, 2024 20:32 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	Exercise / conversionStock Option (Right to Buy) · Derivative	81,550	$0.00 Strike: $5.18	$0.00	Disclosure SEC source: 0001628280-24-027061 · wk-form4_1717705944.xml · derivative · entry 3 Harris Taylor C. · CIK 0001560168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,923 Underlying: Common Stock · 81,550 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Stock option was granted on December 16, 2020 and vests on each monthly anniversary of the grant date over a 4 year period, subject continued employment or service to the Issuer through the applicable vesting date. Read SEC document
June 04, 2024 Filed Jun 6, 2024 20:32 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	GrantCommon Stock	1,376	$0.00	$0.00	Disclosure SEC source: 0001628280-24-027061 · wk-form4_1717705944.xml · nonDerivative · entry 2 Harris Taylor C. · CIK 0001560168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,712 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document
June 04, 2024 Filed Jun 6, 2024 20:32 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	Exercise / conversionCommon Stock	81,550	$5.18	$422,429.00	Disclosure SEC source: 0001628280-24-027061 · wk-form4_1717705944.xml · nonDerivative · entry 1 Harris Taylor C. · CIK 0001560168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 13, 2024 Filed May 14, 2024 18:16 UTC	CUTERA INC CUTR · Entity 82936	GrantStock Option (Right to Buy) · Derivative	200,000	$0.00 Strike: $2.23	$0.00	Disclosure SEC source: 0001628280-24-023325 · wk-form4_1715724975.xml · derivative · entry 1 Harris Taylor C. · CIK 0001560168 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 935,295 Underlying: COMMON STOCK · 200,000 shares Expires 2031-05-13 F1 · derivative.exercise_date: The stock options vest 1/48 per month from April 25, 2024, subject to the Reporting Person continuing to be a service provider of the Company. F2 · derivative.expiration_date: The expiration date is subject to earlier expiration upon the termination of the Reporting Person's service with the Company. Read SEC document
August 29, 2023 Filed Aug 30, 2023 08:57 UTC	CUTERA INC CUTR · Entity 82936	PurchaseCommon Stock	30,000	$9.91	$297,300.00	Disclosure SEC source: 0001209191-23-047680 · doc4.xml · nonDerivative · entry 1 Harris Taylor C. · CIK 0001560168 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 279,336 F1 · price: This transaction was executed in multiple trades at prices ranging from $9.82 to $9.92. The price reported above reflects the weighted average purchase price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate purchase price. Read SEC document
August 18, 2023 Filed Aug 22, 2023 16:27 UTC	CUTERA INC CUTR · Entity 82936	GrantStock Option (Right to Buy) · Derivative	735,295	$0.00 Strike: $11.02	$0.00	Disclosure SEC source: 0001209191-23-046900 · doc4.xml · derivative · entry 2 Harris Taylor C. · CIK 0001560168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 735,295 Underlying: Common Stock · 735,295 shares Expires 2030-08-18 F2 · derivative.exercise_date: One-fourth of the shares subject to the option will be eligible to vest upon the date the 30 calendar-day trailing average closing price of the Company's Common Stock first meets each of the following levels within four years of the grant date: $20.00, $25.00, $30.00, and $35.00. Once a level is attained, one-fourth of the options subject to such tranche will vest on the later of (i) the date such level is attained or (ii) August 7, 2024. The remaining options in such tranche will vest over the next 12 quarters, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
August 18, 2023 Filed Aug 22, 2023 16:27 UTC	CUTERA INC CUTR · Entity 82936	GrantCommon Stock	249,336	$0.00	$0.00	Disclosure SEC source: 0001209191-23-046900 · doc4.xml · nonDerivative · entry 1 Harris Taylor C. · CIK 0001560168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,336 F1 · shares: Grant of Restricted Stock Units (RSU's) that will entitle the Reporting Person to receive one share of Common Stock per one RSU. One-fourth of the RSUs shall vest on August 7, 2024 and 1/12 of the RSUs shall vest each quarter thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
June 15, 2023 Filed Jun 16, 2023 20:46 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	GrantStock Option (Right to Buy) · Derivative	4,865	$0.00 Strike: $35.09	$0.00	Disclosure SEC source: 0001628280-23-022491 · wk-form4_1686948399.xml · derivative · entry 2 Harris Taylor C. · CIK 0001560168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,865 Underlying: Common Stock · 4,865 shares Expires 2033-06-14 F2 · derivative.exercise_date: The Stock Option was granted on June 15, 2023 and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document
June 15, 2023 Filed Jun 16, 2023 20:46 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	GrantCommon Stock	2,711	$0.00	$0.00	Disclosure SEC source: 0001628280-23-022491 · wk-form4_1686948399.xml · nonDerivative · entry 1 Harris Taylor C. · CIK 0001560168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,786 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document
May 19, 2023 Filed May 23, 2023 18:54 UTC	CUTERA INC CUTR · Entity 82936	GrantStock Option (Right to Buy) · Derivative	25,327	$0.00 Strike: $16.84	$0.00	Disclosure SEC source: 0001209191-23-031746 · doc4.xml · derivative · entry 1 Harris Taylor C. · CIK 0001560168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,327 Underlying: Common Stock · 25,327 shares Expires 2030-05-19 F1 · derivative.exercise_date: One-third of the shares subject to the option vest on May 19, 2024 and each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
June 07, 2022 Filed Jun 9, 2022 20:08 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	GrantCommon Stock · Derivative	4,205	$0.00 Strike: $38.85	$0.00	Disclosure SEC source: 0001628280-22-016680 · wf-form4_165480528776041.xml · derivative · entry 2 Harris Taylor C. · CIK 0001560168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,205 Underlying: Common Stock · 4,205 shares Expires 2032-06-06 F2 · price: The Stock option was granted on June 7, 2022 and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. F2 · derivative.exercise_date: The Stock option was granted on June 7, 2022 and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document
June 07, 2022 Filed Jun 9, 2022 20:08 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	GrantCommon Stock	2,001	$37.48	$74,997.48	Disclosure SEC source: 0001628280-22-016680 · wf-form4_165480528776041.xml · nonDerivative · entry 1 Harris Taylor C. · CIK 0001560168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,075 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document
September 17, 2021 Filed Sep 21, 2021 22:35 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	ConversionSeries G Convertible Preferred Stock · Derivative	3,859	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0001628280-21-018958 · wf-form4_163226373965402.xml · derivative · entry 4 Harris Taylor C. · CIK 0001560168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,859 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock , Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock (collectively, the "Preferred Stock") converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date. F1 · price: Each share of Series A Preferred Stock , Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock (collectively, the "Preferred Stock") converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock , Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock (collectively, the "Preferred Stock") converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock , Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock (collectively, the "Preferred Stock") converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date. Read SEC document
September 17, 2021 Filed Sep 21, 2021 22:35 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	ConversionSeries E Convertible Preferred Stock · Derivative	31,215	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0001628280-21-018958 · wf-form4_163226373965402.xml · derivative · entry 3 Harris Taylor C. · CIK 0001560168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,215 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock , Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock (collectively, the "Preferred Stock") converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date. F1 · price: Each share of Series A Preferred Stock , Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock (collectively, the "Preferred Stock") converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock , Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock (collectively, the "Preferred Stock") converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock , Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock (collectively, the "Preferred Stock") converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date. Read SEC document
September 17, 2021 Filed Sep 21, 2021 22:35 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	PurchaseCommon Stock	10,000	$25.00	$250,000.00	Disclosure SEC source: 0001628280-21-018958 · wf-form4_163226373965402.xml · nonDerivative · entry 2 Harris Taylor C. · CIK 0001560168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,074 F2 · shares: Represents a purchase in the Issuer's public offering. Read SEC document
September 17, 2021 Filed Sep 21, 2021 22:35 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	ConversionCommon Stock	35,074	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-21-018958 · wf-form4_163226373965402.xml · nonDerivative · entry 1 Harris Taylor C. · CIK 0001560168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock , Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock (collectively, the "Preferred Stock") converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date. Read SEC document
September 14, 2021 Filed Sep 16, 2021 22:39 UTC	PROCEPT BioRobotics Corp PRCT · Entity 4831	GrantStock Option (Right to Buy) · Derivative	10,308	$0.00 Strike: $25.00	$0.00	Disclosure SEC source: 0001628280-21-018795 · wf-form4_163183194613700.xml · derivative · entry 1 Harris Taylor C. · CIK 0001560168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,308 Underlying: Common Stock · 10,308 shares Expires 2031-09-14 F1 · shares: Option will vest and become exercisable in full on the earlier of September 14, 2022 or the day prior to the date of the 2022 annual meeting of the stockholders, subject to the director's continued service. F1 · price: Option will vest and become exercisable in full on the earlier of September 14, 2022 or the day prior to the date of the 2022 annual meeting of the stockholders, subject to the director's continued service. F1 · derivative.exercise_date: Option will vest and become exercisable in full on the earlier of September 14, 2022 or the day prior to the date of the 2022 annual meeting of the stockholders, subject to the director's continued service. Read SEC document
November 17, 2020 Filed Nov 19, 2020 20:21 UTC	MyoKardia, Inc. MYOK · Entity 145206	Disposition to issuerStock Option (Right to buy) · Derivative	46,060	Not disclosed Strike: $70.40	Not disclosed	Disclosure SEC source: 0000899243-20-031759 · doc4.xml · derivative · entry 4 Harris Taylor C. · CIK 0001560168 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,060 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. Read SEC document
November 17, 2020 Filed Nov 19, 2020 20:21 UTC	MyoKardia, Inc. MYOK · Entity 145206	Disposition to issuerStock Option (Right to buy) · Derivative	49,400	Not disclosed Strike: $40.11	Not disclosed	Disclosure SEC source: 0000899243-20-031759 · doc4.xml · derivative · entry 3 Harris Taylor C. · CIK 0001560168 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,400 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. Read SEC document
November 17, 2020 Filed Nov 19, 2020 20:21 UTC	MyoKardia, Inc. MYOK · Entity 145206	Disposition to issuerStock Option (Right to buy) · Derivative	100,000	Not disclosed Strike: $48.50	Not disclosed	Disclosure SEC source: 0000899243-20-031759 · doc4.xml · derivative · entry 2 Harris Taylor C. · CIK 0001560168 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. Read SEC document
November 17, 2020 Filed Nov 19, 2020 20:21 UTC	MyoKardia, Inc. MYOK · Entity 145206	OtherCommon Stock	42,559	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-031759 · doc4.xml · nonDerivative · entry 1 Harris Taylor C. · CIK 0001560168 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2 · shares: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2 · price: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price. Read SEC document
April 06, 2020 Filed Apr 7, 2020 17:42 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	1,305	$46.99	$61,321.95	Disclosure SEC source: 0000899243-20-010437 · doc4.xml · nonDerivative · entry 2 Harris Taylor C. · CIK 0001560168 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,438 F2 · kind: The disposition of the shares is solely to cover tax withholding obligations resulting from the vesting of RSUs reported herein. Read SEC document
April 04, 2020 Filed Apr 7, 2020 17:42 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionRestricted Stock Units · Derivative	3,750	$0.00	$0.00	Disclosure SEC source: 0000899243-20-010437 · doc4.xml · derivative · entry 3 Harris Taylor C. · CIK 0001560168 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from April 4, 2018, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F3 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from April 4, 2018, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Read SEC document
April 04, 2020 Filed Apr 7, 2020 17:42 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionCommon Stock	3,750	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-010437 · doc4.xml · nonDerivative · entry 1 Harris Taylor C. · CIK 0001560168 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document
February 14, 2020 Filed Feb 19, 2020 20:30 UTC	MyoKardia, Inc. MYOK · Entity 145206	GrantRestricted Stock Units · Derivative	14,871	$0.00	$0.00	Disclosure SEC source: 0000899243-20-005176 · doc4.xml · derivative · entry 2 Harris Taylor C. · CIK 0001560168 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,871 Underlying: Common Stock · 14,871 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2020, so that all of the underlying shares shall be vested on January 1, 2024, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2020, so that all of the underlying shares shall be vested on January 1, 2024, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2020, so that all of the underlying shares shall be vested on January 1, 2024, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Read SEC document
February 14, 2020 Filed Feb 19, 2020 20:30 UTC	MyoKardia, Inc. MYOK · Entity 145206	GrantStock Option (Right to Buy) · Derivative	46,060	$0.00 Strike: $70.40	$0.00	Disclosure SEC source: 0000899243-20-005176 · doc4.xml · derivative · entry 1 Harris Taylor C. · CIK 0001560168 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,060 Underlying: Common Stock · 46,060 shares Expires 2030-02-13 F1 · derivative.exercise_date: The shares underlying the option vest in 48 equal monthly installments from January 1, 2020, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document
January 06, 2020 Filed Jan 7, 2020 19:39 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	1,683	$68.45	$115,203.20	Disclosure SEC source: 0000899243-20-000794 · doc4.xml · nonDerivative · entry 1 Harris Taylor C. · CIK 0001560168 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,993 F1 · kind: Shares sold to cover withholding taxes in connection with vesting of Restricted Stock Units reported on Form 4 filed by the Reporting Person on January 3, 2020. F2 · price: Represents the weighted average sale price of the shares sold ranging from $68.35 to $68.66 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
January 01, 2020 Filed Jan 3, 2020 20:17 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionRestricted Stock Units · Derivative	4,250	$0.00	$0.00	Disclosure SEC source: 0000899243-20-000384 · doc4.xml · derivative · entry 2 Harris Taylor C. · CIK 0001560168 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,750 Underlying: Common Stock · 4,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Read SEC document
January 01, 2020 Filed Jan 3, 2020 20:17 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionCommon Stock	4,250	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-000384 · doc4.xml · nonDerivative · entry 1 Harris Taylor C. · CIK 0001560168 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,676 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document
April 05, 2019 Filed Apr 9, 2019 18:19 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionRestricted Stock Units · Derivative	3,750	$0.00	$0.00	Disclosure SEC source: 0000899243-19-010398 · doc4.xml · derivative · entry 3 Harris Taylor C. · CIK 0001560168 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The units vest in equal annual installments over 4 years from April 4, 2018, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The units vest in equal annual installments over 4 years from April 4, 2018, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Read SEC document
April 05, 2019 Filed Apr 9, 2019 18:19 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	1,324	$53.30	$70,569.20	Disclosure SEC source: 0000899243-19-010398 · doc4.xml · nonDerivative · entry 2 Harris Taylor C. · CIK 0001560168 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,426 F2 · kind: The disposition of the shares is solely to cover tax withholding obligations resulting from the vesting of RSUs reported herein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.